tesmilifene has been researched along with Adenocarcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Avecilla, F; Enyedy, ÉA; Garcia, MH; Gátszegi, GT; Pilon, A; Rácz, B; Robalo, MP; Spengler, G; Valente, A | 1 |
| Brandes, LJ | 1 |
2 other study(ies) available for tesmilifene and Adenocarcinoma
| Article | Year |
|---|---|
Iron(II)-cyclopentadienyl compounds are cytotoxic against colon adenocarcinoma cell lines: Ethylenebis(diphenylphosphane) vs. triphenylphosphane.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Ferrous Compounds; Humans; Hydrogen Peroxide; Iron | 2023 |
N,N-diethyl-2-[4-(phenylmethyl) phenoxy] ethanamine (DPPE; tesmilifene), a chemopotentiating agent with hormetic effects on DNA synthesis in vitro, may improve survival in patients with metastatic breast cancer.
Topics: Adenocarcinoma; Adjuvants, Pharmaceutic; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; DNA, Neoplasm; Dose-Response Relationship, Drug; Female; Humans; Mammary Neoplasms, Experimental; Phenyl Ethers; Platelet Aggregation Inhibitors; Survival Rate; Tumor Cells, Cultured | 2008 |